EA201890402A1 - 5-htрецепторные агонисты и композиции и способы применения - Google Patents

5-htрецепторные агонисты и композиции и способы применения

Info

Publication number
EA201890402A1
EA201890402A1 EA201890402A EA201890402A EA201890402A1 EA 201890402 A1 EA201890402 A1 EA 201890402A1 EA 201890402 A EA201890402 A EA 201890402A EA 201890402 A EA201890402 A EA 201890402A EA 201890402 A1 EA201890402 A1 EA 201890402A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
caused
addiction
sleep
methods
Prior art date
Application number
EA201890402A
Other languages
English (en)
Other versions
EA039412B1 (ru
Inventor
Юрг Леманн
Конрад Файхтингер
Альберт С. Рен
Грейм Сэмпл
Original Assignee
Арена Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арена Фармасьютикалз, Инк. filed Critical Арена Фармасьютикалз, Инк.
Publication of EA201890402A1 publication Critical patent/EA201890402A1/ru
Publication of EA039412B1 publication Critical patent/EA039412B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В некоторых вариантах осуществления обеспечивают соединения формулы A, как определено в настоящем изобретении, которые модулируют активность 5-HTрецептора.В некоторых вариантах осуществления также обеспечивают способы, такие как коррекция веса, стимулирование чувства насыщения и снижение потребления пищи, и предотвращение и лечение ожирения, набора веса, вызванного антипсихотическими средствами, диабета 2 типа, синдрома Прадера-Вилли, зависимости от табака/никотина, наркотической зависимости, алкогольной зависимости, патологического влечения к азартным играм, синдрома дефицита значимости и сексуальной зависимости, заболеваний обсессивно-компульсивного спектра и расстройств контроля над побуждениями (включая привычку грызть ногти и онихофагию), расстройств сна (включая бессонницу, структуру фрагментированного сна и нарушения медленноволнового сна), недержания мочи, психических заболеваний (включая шизофрению, нервную анорексию и нервную булимию), болезни Альцгеймера, сексуальной дисфункции, эректильной дисфункции, эпилепсии, нарушений движения (включая паркинсонизм и нарушение движения, вызванное антипсихотическими средствами), гипертензии, дислипидемии, неалкогольного жирового заболевания печени, заболевания почек, вызванного ожирением, и апноэ во время сна.
EA201890402A 2015-07-31 2016-07-28 5-ht2c рецепторные агонисты и композиции и способы применения EA039412B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31
PCT/US2016/044426 WO2017023679A1 (en) 2015-07-31 2016-07-28 5-ht2c receptor agonists and compositions and methods of use

Publications (2)

Publication Number Publication Date
EA201890402A1 true EA201890402A1 (ru) 2018-09-28
EA039412B1 EA039412B1 (ru) 2022-01-25

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890402A EA039412B1 (ru) 2015-07-31 2016-07-28 5-ht2c рецепторные агонисты и композиции и способы применения

Country Status (14)

Country Link
US (4) US10272094B2 (ru)
EP (1) EP3328835B1 (ru)
JP (1) JP6789578B2 (ru)
KR (1) KR20180031035A (ru)
CN (1) CN108137508B (ru)
AU (1) AU2016302755B2 (ru)
BR (1) BR112018001707A2 (ru)
CA (1) CA3002525A1 (ru)
EA (1) EA039412B1 (ru)
HK (1) HK1255850A1 (ru)
IL (1) IL257107B (ru)
MA (1) MA42527A (ru)
MX (1) MX2018001380A (ru)
WO (1) WO2017023679A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002525A1 (en) * 2015-07-31 2017-02-09 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
NZ578503A (en) * 2003-06-17 2011-02-25 Arena Pharm Inc Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases
JP4773969B2 (ja) * 2003-10-08 2011-09-14 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
CA3002525A1 (en) 2015-07-31 2017-02-09 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
US11395824B2 (en) 2022-07-26
MX2018001380A (es) 2018-06-15
AU2016302755A1 (en) 2018-03-15
HK1255850A1 (zh) 2019-08-30
US20200078368A1 (en) 2020-03-12
EA039412B1 (ru) 2022-01-25
AU2016302755B2 (en) 2020-09-10
BR112018001707A2 (pt) 2018-09-18
US10624900B2 (en) 2020-04-21
CN108137508B (zh) 2021-08-27
IL257107B (en) 2021-03-25
CN108137508A (zh) 2018-06-08
MA42527A (fr) 2021-04-07
EP3328835B1 (en) 2022-10-12
US10272094B2 (en) 2019-04-30
NZ739883A (en) 2021-03-26
KR20180031035A (ko) 2018-03-27
WO2017023679A1 (en) 2017-02-09
US20200383993A1 (en) 2020-12-10
EP3328835A1 (en) 2018-06-06
IL257107A (en) 2018-03-29
US20180214455A1 (en) 2018-08-02
JP6789578B2 (ja) 2020-11-25
US20230055376A1 (en) 2023-02-23
CA3002525A1 (en) 2017-02-09
JP2018522025A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
EA201890402A1 (ru) 5-htрецепторные агонисты и композиции и способы применения
BR112017023088A2 (pt) agonistas do receptor 5-ht2c e composições e métodos de uso
EA201990527A1 (ru) Агонисты рецептора 5-htи композиции, а также способ их применения
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
NZ629198A (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EA200800430A1 (ru) Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
NZ595625A (en) Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
TN2011000463A1 (en) Composition and methods for increasing muscle growth
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
TN2017000158A1 (en) Carbazole derivatives
EA201590406A1 (ru) Мочевинные и амидные производные аминоалкилпиперазинов и их применение
PE20081373A1 (es) Derivados de 5-fenil-nicotinamida
BR112017000160A2 (pt) derivados de azetidina substituidos como ligantes de taar
JP2014532063A5 (ru)
DE602005016836D1 (de) Chotischer und anxiolytischer aktivität
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX2016001080A (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
MX2015012459A (es) Polimorfos y sales de un compuesto.